Pemafibrate
As of the edition of 20 October 2026, Pemafibrate is a small molecule: marketed, first approved in 2017 (JP); acts on PPARA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Parmodia
- First approved
- 3 July 2017 (JP)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Kowa
- Registered trials
- 6, 1 stopped early
- Disease areas
- Digestive system; Heart and blood vessels; Nutrition and metabolism; Eye; Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kowa | Applicant and Lead sponsor of trials | 2017 to now |